Also found in: Dictionary, Thesaurus, Acronyms, Wikipedia.


trademark for a preparation of gemfibrozil, an antilipidemic agent.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


Apo-Gemfibrozil (CA), Dom-Gemfibrozil (CA), Gen-Gemfibrozil (CA), Lopid, Novo-Gemfibrozil (CA), Nu-Gemfibrozil (CA), PMS-Gemfibrozil (CA), Riva-Gemfibrozil (CA)

Pharmacologic class: Fibric acid derivative

Therapeutic class: Antihyperlipidemic

Pregnancy risk category C


Inhibits peripheral lipolysis, resulting in decreased triglyceride levels. Also inhibits synthesis and increases clearance of very-low-density lipoproteins.


Tablets: 600 mg

Indications and dosages

Type IIb hyperlipidemia in patients without coronary artery disease who don't respond to other treatments; adjunctive therapy for types IV and V hyperlipidemia

Adults: 1,200 mg P.O. daily in two divided doses


• Hypersensitivity to drug

• Gallbladder disease

• Severe renal dysfunction

• Hepatic dysfunction


Use cautiously in:

• renal impairment, cholelithiasis, diabetes, hypothyroidism

• pregnant or breastfeeding patients

• children (safety not established).


• Give 30 minutes before a meal.

• Know that before starting drug and throughout therapy, patient should use dietary measures and exercise, as appropriate, to control hyperlipidemia.

Adverse reactions

CNS: fatigue, hypoesthesia, paresthesia, drowsiness, syncope, vertigo, dizziness, headache, seizures

CV: vasculitis

EENT: cataracts, blurred vision, retinal edema, hoarseness

GI: nausea, vomiting, diarrhea, abdominal or epigastric pain, heartburn, flatulence, gallstones, dry mouth

GU: dysuria, erectile dysfunction, decreased male fertility

Hematologic: eosinophilia, anemia, bone marrow hypoplasia, leukopenia, thrombocytopenia

Hepatic: hepatotoxicity

Metabolic: hypoglycemia

Musculoskeletal: joint, back, or muscle pain; myasthenia; myopathy; synovitis; myositis; rhabdomyolysis

Respiratory: cough

Skin: alopecia, rash, urticaria, eczema, pruritus, angioedema

Other: abnormal taste, chills, weight loss, increased risk of bacterial and viral infection, lupuslike syndrome, anaphylaxis


Drug-drug. Chenodiol, ursodiol: decreased gemfibrozil efficacy

Cyclosporine: decreased cyclosporine effects

HMG-CoA reductase inhibitors: increased risk of rhabdomyolysis

Sulfonylureas: increased hypoglycemic effects

Warfarin: increased bleeding risk

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, creatine kinase (CK), glucose, lactate dehydrogenase: increased values

Hematocrit, hemoglobin, potassium, white blood cells: decreased values

Patient monitoring

• Monitor kidney and liver function test results and serum lipid levels.

Watch for signs and symptoms of adverse reactions, especially bleeding tendency and hypersensitivity reaction.

• Monitor periodic blood counts during first year of therapy.

• Check CK level if myopathy occurs.

Patient teaching

• Tell patient to take drug 30 minutes before breakfast and dinner.

Advise patient to immediately report signs or symptoms of anaphylaxis (such as difficulty breathing or rash) or other allergic reactions.

Instruct patient to immediately report unusual bleeding or bruising or muscle pain.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• Stress importance of diet and exercise in lowering lipid levels.

• Inform patient that he'll undergo regular blood testing during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


A trademark for the drug gemfibrozil.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


Gemfibrozil, see there.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.


A brand name for GEMFIBROZIL.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Who is at risk: Elderly patients, those who took a high dosage of Baycol, and those who also took Baycol and gemfibrozil (Lopid).
A spokeswoman said: "There is a rare but serious reaction when Lipobay is used together with Lopid.
The group's book, Worst Pills, Best Pills II (1993), advises consumers not to use Lopid. "There is no proof that gemfibrozil has any hea lth benefit," the book says.
The most widely used fibrate in the United States is gemfibrozil (Lopid).
Fenofibrate (Tricor) 67 to 200 mg per day or gemfibrozil (Lopid) 600 mg twice a day are effective in lowering triglyceride levels, and have some effect on cholesterol as well.
In addition to those medications, it launched gemfibrozil, a cholesterol-lowering agent that's similar to Parke-Davis' Lopid tablets; alprazolam, an antianxiety drug that's a generic version of Upjohn Co.'s Xanax; and naproxen, an analgesic that offers a generic alternative to Syntex Laboratories Inc.'s Naprosyn.
This placebo-controlled, double-blind drug trial in Finland is examining the lipoprotein-altering impacts of gemfibrozil (Lopid) on heart attack rates in 4,081 apparently healthy men aged 40 to 55.
In addition, this time he was placed on the lipid-lowering drug Lopid. Soon his total cholesterol level had dropped to 156 mg/dl.
Fibrate medications include gemfibrozil (Lopid), fenofibrate (TriCor) and clofibrate (Atromid-S).
* Fenofibrates (Tricor, Antara) and gemfibrozil (Lopid) are considered third-line drugs used for lowering triglycerides and raising HDL.
Use of Vytorin while consuming large quantities of grapefruit or taking drugs such as cyclosporine (Sandimmune), amiodarone (Cordarone), erythromycin, niacin and gemfibrozil (Lopid) may increase your risk of serious side effects.
Compared with placebo, gemfibrozil (Lopid) cut triglycerides by 55.0 mg/dL, cut total cholesterol by 6.7 mg/dL, and raised HDL cholesterol by 2.3 mg/dL.